COMBINED EFFECTS OF ZOLEDRONIC ACID AND SODIUM PENTABORATE PENTAHYDRATE ON PROLIFERATION, MIGRATION AND APOPTOSIS OF HUMAN NEUROBLASTOMA CELL LINE

Year 2021, Volume: 7 Issue: 1, 24 - 35, 30.06.2021

Hüseyin Abdik

https://doi.org/10.51477/mejs.936674

Cited By: 2

Abstract

Neuroblastoma is one of the most common solid tumor in children with high aggressiveness. Although there are many different strategies to fight the neuroblastoma including surgical treatment, chemotherapy, radiotherapy, and immunotherapy, ultimately successful treatment has not been evaluated yet. Effective, safe, and less toxic options must be investigated. Zoledronic acid (ZOL) is a type of amino-bisphosphonates and has been used in bone-related diseases for more than 20 years and anti-tumor ability of the ZOL is known. Boron is a natural product and many regenerative properties of boron compounds such as myogenic, osteogenic, and odontogenic induction potential have been discovered. Besides, the boron compound also displayed anti-cancer characteristics in different studies. In the current study, we evaluated the possible synergistic effects of the ZOL and Sodium pentaborat tetrahydrate (SPT) on the neuroblastoma cells, SHSY5Y. As a result, ZOL and SPT combination exhibited the most favorable anti-proliferative, pro-apoptotic and anti-migratory effects compared to the ZOL and SPT alone and control groups. Moreover, molecular evidences have indicated that while expression of the proliferative gene, NFκB was significantly decreased in combination group compared to all other groups, pro-apoptotic genes, were overexpressed. To sum up, obtained results from the recent study lead it necessary to carry out more detailed studies.

Keywords

Neuroblastoma, Zoledronic acid, Sodium pentaborat tetrahydrate, Apoptosis

Thanks

This study was supported by Yeditepe University

References

• [1] S. B. Whittle, V. Smith, E. Doherty, S. Zhao, S. McCarty, and P. E. Zage, “Overview and recent advances in the treatment of neuroblastoma,” Expert Rev. Anticancer Ther., vol. 17, no. 4, pp. 369–386, 2017.
• [2] P. D. Q. P. T. E. Board, “Neuroblastoma Treatment (PDQ®),” in PDQ Cancer Information Summaries, National Cancer Institute (US), 2020.
• [3] G. M. Brodeur, “Neuroblastoma: biological insights into a clinical enigma,” Nat. Rev. Cancer, vol. 3, no. 3, pp. 203–216, 2003, doi: 10.1038/nrc1014.
• [4] H. Bassiri, A. Benavides, M. Haber, S. K. Gilmour, M. D. Norris, and M. D. Hogarty, “Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma,” Transl. Pediatr., vol. 4, no. 3, p. 226, 2015.
• [5] R. G. G. Russell, “Bisphosphonates: mode of action and pharmacology,” Pediatrics, vol. 119, no. Supplement 2, pp. S150--S162, 2007.
• [6] G. I. Baroncelli and S. Bertelloni, “The use of bisphosphonates in pediatrics,” Horm. Res. Paediatr., vol. 82, no. 5, pp. 290–302, 2014.
• [7] N. Kohno et al., “Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial,” J. Clin. Oncol., vol. 23, no. 15, pp. 3314–3321, 2005.
• [8] F. Daubiné, C. Le Gall, J. Gasser, J. Green, and P. Clézardin, “Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis,” J. Natl. Cancer Inst., vol. 99, no. 4, pp. 322–330, 2007.
• [9] F. H. Nielsen, “Update on human health effects of boron,” J. Trace Elem. Med. Biol., vol. 28, no. 4, pp. 383–387, 2014.
• [10] R. I Scorei and R. Popa, “Boron-containing compounds as preventive and chemotherapeutic agents for cancer,” Anti-Cancer Agents Med. Chem. (Formerly Curr. Med. Chem. Agents), vol. 10, no. 4, pp. 346–351, 2010.
• [11] S. Mahabir, M. R. Spitz, S. L. Barrera, Y. Q. Dong, C. Eastham, and M. R. Forman, “Dietary boron and hormone replacement therapy as risk factors for lung cancer in women,” Am. J. Epidemiol., vol. 167, no. 9, pp. 1070–1080, 2008.
• [12] F. Xu et al., Advances in plant and animal boron nutrition. Springer, 2007.
• [13] Y. Cui et al., “Dietary boron intake and prostate cancer risk,” Oncol. Rep., vol. 11, no. 4, pp. 887–892, 2004.
• [14] S. Ackermann et al., “A mechanistic classification of clinical phenotypes in neuroblastoma,” Science (80-. )., vol. 362, no. 6419, pp. 1165–1170, 2018, doi: 10.1126/science.aat6768.
• [15] N. M. La-Beck, X. Liu, H. Shmeeda, C. Shudde, and A. A. Gabizon, “Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment,” 2019.
• [16] A. C. Hirbe et al., “The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts,” Bone, vol. 44, no. 5, pp. 908–916, 2009.
• [17] V. Stresing et al., “Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase,” Bone, vol. 48, no. 2, pp. 259–266, 2011.
• [18] S. Dhesy-Thind et al., “Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline,” J Clin Oncol, vol. 35, no. 18, pp. 2062–2081, 2017.
• [19] P. N. Taşlı, A. Doğan, S. Demirci, and F. Şahin, “Boron Enhances Odontogenic and Osteogenic Differentiation of Human Tooth Germ Stem Cells (hTGSCs) In Vitro,” Biol. Trace Elem. Res., vol. 153, no. 1, pp. 419–427, 2013, doi: 10.1007/s12011-013-9657-0.
• [20] H. Apdik, A. Doğan, S. Demirci, S. Aydın, and F. Şahin, “Dose-dependent Effect of Boric Acid on Myogenic Differentiation of Human Adipose-derived Stem Cells (hADSCs),” Biol. Trace Elem. Res., vol. 165, no. 2, pp. 123–130, 2015, doi: 10.1007/s12011-015-0253-3.
• [21] Q. Jiang, Q. Zhong, Q. Zhang, S. Zheng, and G. Wang, “Boron-based 4-hydroxytamoxifen bioisosteres for treatment of de novo tamoxifen resistant breast cancer,” ACS Med. Chem. Lett., vol. 3, no. 5, pp. 392–396, 2012.
• [22] H. Hernández-López et al., “Synthesis of Hybrid Fluoroquinolone-Boron Complexes and Their Evaluation in Cervical Cancer Cell Lines,” J. Chem., vol. 2019, p. 5608652, 2019, doi: 10.1155/2019/5608652.
• [23] T. B. Hayal et al., “Lead Borate Nanoparticles Induce Apoptotic Gene Activity in P53 Mutant Cancer Cells,” Biol. Trace Elem. Res., 2021, doi: 10.1007/s12011-021-02696-0.
• [24] E. Avsar Abdik, F. Kaleagasioglu, H. Abdik, F. Sahin, and M. R. Berger, “ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling,” Anticancer. Drugs, vol. 30, no. 4, pp. 383–393, 2019.
• [25] J.-W. Hyun et al., “Radiation sensitivity depends on OGG1 activity status in human leukemia cell lines,” Free Radic. Biol. Med., vol. 32, no. 3, pp. 212–220, 2002.
• [26] T. Ara and Y. A. DeClerck, “Mechanisms of invasion and metastasis in human neuroblastoma,” Cancer Metastasis Rev., vol. 25, no. 4, pp. 645–657, 2006, doi: 10.1007/s10555-006-9028-9.
• [27] Y. Savci et al., “Grapefruit Derived Extracellular Vesicles as a Promising Cell-free Therapeutic Tool for Wound Healing,” Food Funct., 2021.
• [28] A. R. Hussain et al., “Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis,” PLoS One, vol. 7, no. 6, p. e39945, 2012.
• [29] W. Li et al., “An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro,” Mol. Cell. Biochem., vol. 363, no. 1, pp. 135–145, 2012.
• [30] L. Lindenboim et al., “Apoptotic stress induces Bax-dependent, caspase-independent redistribution of LINC complex nesprins,” Cell Death Discov., vol. 6, no. 1, p. 90, 2020, doi: 10.1038/s41420-020-00327-6.
• [31] L. Du, Z. Fei, S. Song, and N. Wei, “Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio,” Biomed. Pharmacother., vol. 95, pp. 447–452, 2017, doi: https://doi.org/10.1016/j.biopha.2017.08.119.